Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Prognosis of FLT3 ligand level in newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial

Blood (2025) 146 (Supplement 1): 1694.

https://doi.org/10.1182/blood-2025-1694

Published: 2025

Journal Articles

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial

Blood (2025) 146 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2025-1719

Published: 2025

Journal Articles

Real-world outcomes of FLAG-ida salvage therapy in relapsed/refractory AML and validation of the salflage score: A pethema registry study

Gaspar Aspas Requena, Rebeca Rodriguez-Veiga, Cristina Gil, Carmen Botella, Eliana Aguiar, Fernanda Trigo, Mercedes Colorado, Teresa Bernal Del Castillo, Eva Barragán, Mar Tormo, Eduardo Rodríguez-Arbolí, Josefina Serrano, Raimundo García-Boyero, Tamara Castaño, Pilar Herrera Puente, Monica Romero, Maria Jose Sayas Lloris, Lorenzo Algarra, Carlos Rodríguez-Medina, Claudia Sossa, Jorge Labrador, Susana Vives, María Luz Amigo, Olga Salamero, Marta Valero Núñez, Christine Rojas, Veronica Lizama, María García-Fortes, María-Belén Vidriales, Celina Benavente, Maria Dolores Madrigal, Marcela Espinoza, Manuel Pérez-Encinas, María Lourdes Amador Barciela, Guiomar Bautista Carrascosa, Antonio Solana-Altabella, Isabel Cano-Ferri, Rafael Colmenares, David Martinez-Cuadron, Stefan Wickenhauser, Juan Miguel Bergua Burgues, Pau Montesinos

Blood (2025) 146 (Supplement 1): 1619.

https://doi.org/10.1182/blood-2025-1619

Published: 2025

Journal Articles

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

Bruno Paiva, Leire Burgos, Carmen Gonzalez, Rebeca Rodriguez Veiga, Antonio Solana-Altabella, Pilar Lloret-Madrid, Evelyn Acuña-Cruz, Cristina Gil, Carmen Botella, Eduardo Rodríguez-Arbolí, Teresa Caballero, Teresa Bernal Del Castillo, Maria Teresa Cedena Romero, Pilar Herrera Puente, Claudia Sossa, Josefina Serrano, Joaquín Sánchez-García, José Luis López Lorenzo, María-Belén Vidriales, Mar Tormo, Monica Romero, Mercedes Colorado, Celina Benavente, Juan Miguel Bergua Burgues, Manuel Pérez-Encinas, Lorenzo Algarra, Carlos Rodríguez-Medina, Dolly Viviana Fiallo Suarez, Raimundo García-Boyero, Luis Felipe Casado Montero, Jorge Labrador, Manuel Barrios García, Beatriz De Rueda Ciller, Marcela Espinoza, Maria Jose Sayas Lloris, Diana Cuervo, María Luz Amigo, Jose-Mario Mariz, Karoll Giovanna Gomez Correcha, Carmen Couto, Esther Perez, Ágata Almela, Susana Vives, Esperanza Lavilla-Rubira, Olga Arce-Fernández, Maria Teresa Olave Rubio, Miguel Lopez, Maria Dolores Madrigal, Lara María Gómez García, Sofia Grille, Sebastián Hidalgo, Daniel García Belmonte, Maria Jose Garcia, Maria Del Carmen Martinez Chamorro, Olga Salamero, Amparo Sempere, Beatriz Martín Herreros, Armando Mena Duran, David Martinez-Cuadron, Pau Montesinos

Blood (2025) 146 (Supplement 1): 5293.

https://doi.org/10.1182/blood-2025-5293

Published: 2025

Journal Articles

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Blood (2023) 141 (2): 156–167.

https://doi.org/10.1182/blood.2021014901

Published: 2023

Includes: Supplemental data

Journal Articles

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Blood (2022) 140 (Supplement 1): 9100–9102.

https://doi.org/10.1182/blood-2022-163016

Published: 2022

Journal Articles

Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 2270–2272.

https://doi.org/10.1182/blood-2022-163159

Published: 2022

Journal Articles

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia

Hardikkumar Jetani, Almudena Navarro-Bailón, Marius Maucher, Silke Frenz, Christina Verbruggen, Ana Yeguas, María Belén Vidriales, Marcos González, Judit Rial Saborido, Sabrina Kraus, Katrin Mestermann, Simone Thomas, Halvard Bonig, Maik Luu, Razieh Monjezi, Dimitrios Mougiakakos, Markus Sauer, Hermann Einsele, Michael Hudecek

Blood (2021) 138 (19): 1830–1842.

https://doi.org/10.1182/blood.2020009192

Published: 2021

Includes: Supplemental data

Journal Articles

Venetoclax Therapy in a Heavily Treated Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia: Update of the Pethema Registry Experience

Blood (2021) 138 (Supplement 1): 2325.

https://doi.org/10.1182/blood-2021-150231

Published: 2021

Journal Articles

Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Paterns from Dysplasia to Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 520.

https://doi.org/10.1182/blood-2021-145737

Published: 2021

Journal Articles

Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Teresa Caballero, Olga Pérez-López, Ana Yeguas Bermejo, Eduardo Rodriguez Arbolí, Enrique Colado Varela, Maria Desamparados Sampere Talens, María Belén Vidriales, Covadonga Quirós Caso, Marta Reinoso Segura, Concepción Prats-Martín, Pau Montesinos, Jose A. Perez-Simon

Blood (2021) 138 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2021-151533

Published: 2021

Journal Articles

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Blood (2021) 137 (1): 49–60.

https://doi.org/10.1182/blood.2020006731

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Pilar Martínez, MD, Tomás Palanques Pastor, Jose Luiz Lopez Lorenzo, MD, Javier Cornago Navascués, MD, Gabriela Rodriguez-Macías, MD, Isabel Cano, MD, Montserrat Arnan Sangerman, María-Belén Vidriales, MDPhD, Jesús Lorenzo Algarra, Maria Angeles Foncillas, Pilar Herrera Puente, Carmen Botella, Susana Vives, MD, Angela Figuera Alvarez, MD PhD, Laida Cuevas Palomares, Marta Sobas, MDPhD, Alejandro Contento-Gonzalo, MD, Rebeca Cuello, MD, María Elena Amutio Diez, MD, Maria Dunia De Miguel, MD, Begoña Navas, MD, Juan Miguel Bergua Burgues, MD, Teresa Bernal del Castillo, MD PhD, María Carmen Mateos Rodríguez, MD, Erik de Cabo López, MD, Ana Carolina Franco Villegas, MD, Raimundo García-Boyero, MD, Cristian Escolano Escobar, MD, Cristina Seri, MD, Carlos Cervero, MD, Alicia Roldán Pérez, Maria Lourdes Hermosin, MD, Marta Cervera, MD, María Teresa Olave, MD, Paola Sandra Villafuerte Gutierrez, MD, Almudena De Laiglesia, MD, Josefina Serrano, MD, María Josefa Najera Irazu, MD, Jose Luis Piñana Sanchez, Miguel Ángel Sanz, MD, Joaquin Martinez-Lopez, MD, Pau Montesinos, MD PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138471

Published: 2020

Journal Articles

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The Pethema Registry Experience

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-141191

Published: 2020

Journal Articles

Impact of Measurable Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC): A Real-World Study in 1,076 Patients with Acute Myeloid Leukemia (AML)

Bruno Paiva, PhD, María Belén Vidriales, Maria Desamparados Sampere Talens, Fabian Tarin, Enrique Colado, Celina Benavente, María Teresa Cedena, MD, Joaquin Sanchez, MD, Teresa Caballero-Velázquez, MD PhD, Lourdes Cordon, David Martínez-Cuadron, MD, Teresa Bernal del Castillo, MD PhD, Carmen Botella, Sofia Grille, MDPhD, Josefina Serrano, MD, Carlos Rodriguez, Jesús Lorenzo Algarra, Juan Manuel Alonso Dominguez, MD PhD MSc, Maria Luz Amigo, MD, Manuel BARRIOS García, MDPhD, Raimundo García-Boyero, MD, Mercedes Colorado, MD, Jaime Perez De Oteyza, MDPhD, Manuel Perez Encinas, MD, Lissette Del Pilar Costilla, MD, Maria Jose Sayas, Olga Pérez-López, Marcos González, Jose A. Perez-Simon, MD PhD, Joaquin Martinez-Lopez, MD PhD, Claudia Lucia Sossa, Alberto Orfao, MD PhD, Jesús F. San-Miguel, Miguel Sanz, MD PhD, Pau Montesinos, MD PhD

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-134349

Published: 2020

Journal Articles

Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-134651

Published: 2020

Journal Articles

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Blood (2019) 134 (Supplement_1): 3891.

https://doi.org/10.1182/blood-2019-127187

Published: 2019

Journal Articles

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Jinhong Fan, Hongbin Wang, Suzana Couto, Tsun-Wen Sheena Yao, Geoffrey L. Uy, MD, Amer M. Zeidan, MBBS, MHS, Mark D. Minden, Pau Montesinos, Daniel J. DeAngelo, Jessica K. Altman, Jamie Koprivnikar, MD, Paresh Vyas, MD PhD, Yngvar Fløisand, María Belén Vidriales, Bjørn Tore Gjertsen, Tonia J. Buchholz, Michael Pourdehnad, Daniel W. Pierce

Blood (2019) 134 (Supplement_1): 2547.

https://doi.org/10.1182/blood-2019-124291

Published: 2019

Journal Articles

Altered Immunophenotypes on Leukemic and/or Monocytic Cells from Acute Myeloid Leukemia Highly Predict for Nucleophosmin Gene Mutation

Blood (2019) 134 (Supplement_1): 2687.

https://doi.org/10.1182/blood-2019-131733

Published: 2019

Journal Articles

Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry

Blood (2019) 134 (Supplement_1): 1321.

https://doi.org/10.1182/blood-2019-128568

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognosis of FLT3 ligand level in newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial

Real-world outcomes of FLAG-ida salvage therapy in relapsed/refractory AML and validation of the salflage score: A pethema registry study

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia

Venetoclax Therapy in a Heavily Treated Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia: Update of the Pethema Registry Experience

Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Paterns from Dysplasia to Acute Myeloid Leukemia (AML)

Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The Pethema Registry Experience

Impact of Measurable Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC): A Real-World Study in 1,076 Patients with Acute Myeloid Leukemia (AML)

Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Altered Immunophenotypes on Leukemic and/or Monocytic Cells from Acute Myeloid Leukemia Highly Predict for Nucleophosmin Gene Mutation

Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only